Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer

NARecruitingINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Esophagus Cancer
Interventions
PROCEDURE

CRT

"Drug: Capecitabine(Aibin) capecitabine(Aibin):625mg/m2, bid d1-5; q1w, po,5 weeks in total~Other Names:~Aibin Drug: Oxaliplatin(Aiheng) Oxaliplatin(Aiheng):65mg/m2,d1,8, 22, 29,I.V.~Other Names:~Aiheng cisplatin: 75mg/m2 d1,29 or d1, 29, 57, 85. 5-Fu:750mg/m2 CIV24h d1-4,d29-32 or d1-4,d29-32, d57-60, d85-88.~Radiation: Radiotherapy concurrent radiotherapy:IMRT radiotherapy 50Gy in total,2 Gy/d,5d/w,Until disease progression or unacceptable toxicity"

PROCEDURE

surgery

The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy

Trial Locations (2)

471003

RECRUITING

The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang

Unknown

RECRUITING

Anyang Tumor Hospital, Anyang

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

collaborator

Anyang Tumor Hospital

OTHER

collaborator

150th Hospital of PLA

OTHER_GOV

lead

The First Affiliated Hospital of Henan University of Science and Technology

OTHER